![Arthur Roach](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Arthur Roach
Directeur/Membre du Conseil chez NRG Therapeutics Ltd.
Postes actifs de Arthur Roach
Sociétés | Poste | Début | Fin |
---|---|---|---|
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Directeur/Membre du Conseil | 26/04/2023 | - |
Président | - | 26/04/2023 |
Historique de carrière de Arthur Roach
Anciens postes connus de Arthur Roach
Sociétés | Poste | Début | Fin |
---|---|---|---|
Chord Therapeutics SA
![]() Chord Therapeutics SA BiotechnologyHealth Technology Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland. | Fondateur | 01/02/2014 | - |
Statistiques
Internationale
Suisse | 2 |
Royaume-Uni | 2 |
Opérationnelle
Founder | 1 |
Director/Board Member | 1 |
Chairman | 1 |
Sectorielle
Health Technology | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 2 |
---|---|
Chord Therapeutics SA
![]() Chord Therapeutics SA BiotechnologyHealth Technology Chord Therapeutics SA is a clinical stage pharmaceutical company. It develops drugs for patients with rare, life-threatening and severely disabling diseases. The firm offers CRD1. The company was founded by Arthur Roach and is headquartered in Geneva, Switzerland. | Health Technology |
NRG Therapeutics Ltd.
![]() NRG Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services NRG Therapeutics Ltd. is a British neuroscience drug discovery company that focuses on building a pipeline of disease-modifying mitochondrial therapeutics to slow or halt the progression of neurodegenerative disorders such as Parkinson's and ALS. The company is based in Stevenage, UK, and was founded in 2018 by Neil Miller and Richard Rutter. The company's pre-clinical pipeline of small molecule assets is based on inhibiting the mitochondrial permeability transition pore (mptp) through a novel mechanism of action. Inhibition of the mptp has been shown to protect neurons, reduce neuroinflammation, and extend survival in pre-clinical disease models. Neil Miller has been the CEO since 2018. | Commercial Services |
- Bourse
- Insiders
- Arthur Roach
- Expérience